coronavac inactivated virus vaccine (Janssen)
86
Structured Review
Janssen
coronavac inactivated virus vaccine
Coronavac Inactivated Virus Vaccine, supplied by Janssen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/coronavac+inactivated+virus+vaccine/coronavac+inactivated+vaccine+virus/pm40708376-59-5-31
Average 86 stars, based on 1 article reviews
Coronavac Inactivated Virus Vaccine, supplied by Janssen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/coronavac+inactivated+virus+vaccine/coronavac+inactivated+vaccine+virus/pm40708376-59-5-31
Average 86 stars, based on 1 article reviews
coronavac inactivated virus vaccine - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Vaccines:Article Title: Risk Factors for Breakthrough Acute SARS-CoV-2 Infections in Fully Vaccinated Individuals: A Case-Control Study Nested in a Prospective Cohort in Medelln, Colombia. Article Snippet: To effectively curb coronavirus disease 2019 (COVID‐19), it is essential to understand the risk factors for breakthrough acute infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) despite vaccination.. We conducted a case‐control study to assess risk factors for acute SARS‐CoV‐2 infections requiring hospitalization in vaccinated individuals.. The study included 50 vaccinated patients who experienced breakthrough infections requiring hospitalization (inpatient cohort) and 250 control participants from the outpatient cohort of the “Genomic Surveillance and Immune Response Monitoring for COVID‐19 in the Metropolitan Area of the Aburrá Valley, Medellín‐Colombia”. Virus:Article Title: Risk Factors for Breakthrough Acute SARS-CoV-2 Infections in Fully Vaccinated Individuals: A Case-Control Study Nested in a Prospective Cohort in Medelln, Colombia. Article Snippet: To effectively curb coronavirus disease 2019 (COVID‐19), it is essential to understand the risk factors for breakthrough acute infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2) despite vaccination.. We conducted a case‐control study to assess risk factors for acute SARS‐CoV‐2 infections requiring hospitalization in vaccinated individuals.. The study included 50 vaccinated patients who experienced breakthrough infections requiring hospitalization (inpatient cohort) and 250 control participants from the outpatient cohort of the “Genomic Surveillance and Immune Response Monitoring for COVID‐19 in the Metropolitan Area of the Aburrá Valley, Medellín‐Colombia”. |